Percentage of partial cytogenetic responses, complete cytogenetic responses, and partial plus complete, or major, cytogenetic responses, and 5-year survival in the main chronic myeloid leukemia studies of interferon-α alone or in combination with low-dose arabinosyl cytosine
| Study . | Year . | Treatment . | Cases, no. . | PCgR, % . | CCgR, % . | MCgR (PCgr + CCgR), % . | 5-year survival, % . |
|---|---|---|---|---|---|---|---|
| Hehlmann et al8-1504 | 1994 | IFN-α | 133 | 1.5 | 4.5 | 6.0 | 58 |
| Allan et al8-1505 | 1995 | IFN-α | 293 | 5.8 | 4.4 | 10.2 | 50 |
| Lindauer et al8-15118 | 1999 | IFN-α + LDAC | 65 | 6.1 | 4.6 | 10.7 | 56 |
| Ohnishi et al8-1506 | 1995 | IFN-α | 85 | 8.2 | 7.0 | 15.2 | 63 |
| Benelux CML Study Group8-15014 | 1988 | IFN-α | 100 | 7.0 | 9.0 | 16.0 | 54 |
| This study8-152 | 2002 | IFN-α | 263 | 10.3 | 7.6 | 17.98-155 | 65 |
| Italian Cooperative Study Group on CML8-1503 | 1994 | IFN-α | 218 | 11.0 | 7.8 | 18.8 | 60 |
| Guilhot et al8-15216 | 1997 | IFN-α | 361 | 13.0 | 7.8 | 20.88-154 | 62 |
| Ozer et al8-15335 | 1993 | IFN-α | 112 | 15.2 | 12.5 | 27.7 | 54 |
| This study8-152 | 2002 | IFN-α + LDAC | 275 | 14.2 | 14.2 | 28.48-155 | 68 |
| Kloke et al8-15136 | 2000 | IFN-α | 71 | 16.8 | 12.7 | 29.6 | 60 |
| Guilhot et al8-15216 | 1997 | IFN-α + LDAC | 360 | 22.2 | 12.7 | 34.98-154 | 70 |
| Kantarjian et al8-1517 | 1995 | IFN-α | 274 | 11.7 | 26.3 | 38.0 | 62 |
| Kantarjian et al8-15117 | 1999 | IFN-α + LDAC | 186 | 17.7 | 27.4 | 45.1 | 688-159 |
| Study . | Year . | Treatment . | Cases, no. . | PCgR, % . | CCgR, % . | MCgR (PCgr + CCgR), % . | 5-year survival, % . |
|---|---|---|---|---|---|---|---|
| Hehlmann et al8-1504 | 1994 | IFN-α | 133 | 1.5 | 4.5 | 6.0 | 58 |
| Allan et al8-1505 | 1995 | IFN-α | 293 | 5.8 | 4.4 | 10.2 | 50 |
| Lindauer et al8-15118 | 1999 | IFN-α + LDAC | 65 | 6.1 | 4.6 | 10.7 | 56 |
| Ohnishi et al8-1506 | 1995 | IFN-α | 85 | 8.2 | 7.0 | 15.2 | 63 |
| Benelux CML Study Group8-15014 | 1988 | IFN-α | 100 | 7.0 | 9.0 | 16.0 | 54 |
| This study8-152 | 2002 | IFN-α | 263 | 10.3 | 7.6 | 17.98-155 | 65 |
| Italian Cooperative Study Group on CML8-1503 | 1994 | IFN-α | 218 | 11.0 | 7.8 | 18.8 | 60 |
| Guilhot et al8-15216 | 1997 | IFN-α | 361 | 13.0 | 7.8 | 20.88-154 | 62 |
| Ozer et al8-15335 | 1993 | IFN-α | 112 | 15.2 | 12.5 | 27.7 | 54 |
| This study8-152 | 2002 | IFN-α + LDAC | 275 | 14.2 | 14.2 | 28.48-155 | 68 |
| Kloke et al8-15136 | 2000 | IFN-α | 71 | 16.8 | 12.7 | 29.6 | 60 |
| Guilhot et al8-15216 | 1997 | IFN-α + LDAC | 360 | 22.2 | 12.7 | 34.98-154 | 70 |
| Kantarjian et al8-1517 | 1995 | IFN-α | 274 | 11.7 | 26.3 | 38.0 | 62 |
| Kantarjian et al8-15117 | 1999 | IFN-α + LDAC | 186 | 17.7 | 27.4 | 45.1 | 688-159 |
Studies are ordered according to the percentage of MCgR, from the lowest to the highest. Because 2 of the studies, this study and the French study,16 studied 2 treatment arms, each of these studies appears twice as row headings. Note also that the percentage of CgR may be lower than reported in each original paper because, wherever possible, CgR was calculated again on the basis of all enrolled cases, according to the intention-to-treat principle. The data show that the relationship between the MCgR rate and 5-year survival is extremely variable.
PCgR indicates partial cytogenetic response; CCgR, complete cytogenetic response; CML, chronic myeloid leukemia. Other abbreviations are explained in Tables 1 and 4.
Multicenter prospective study of IFN-α versus chemotherapy.
Single-center study.
Multicenter prospective study of IFN-α versus IFN-α + LDAC.
Multicenter prospective study of IFN-α alone.
Calculated at 2 years.
Calculated at 1 year.
Calculated for 140 patients who received LDAC daily.